Texas is quickly becoming one of the most exciting places in the U.S. for life sciences. With a business-friendly tax system, expanding research institutions, and a growing talent pipeline, the state is attracting serious attention from major companies and investors. The sector now contributes an estimated $75 billion annually to the Texas economy.

 

When global pharma giant Eli Lilly announced its expansion into Texas, it sent a clear signal: the state is ready to play in the big leagues. The planned $6.5 billion manufacturing facility in Houston’s Generation Park, which is expected to create over 600 high-wage jobs and thousands of construction jobs, is a colossal investment designed to produce next-generation synthetic medicines, including an oral GLP-1 receptor agonist. For years, local leaders talked about the need for “anchor companies” – large, stable players to keep talent in Texas. That moment has arrived.

 

The life sciences ecosystem is still developing, but its trajectory is unmistakable. Texas has the talent, space, and ambition to become one of the nation’s leading hubs for biotech, medtech and health innovation.

 

This report examines what’s driving that growth, where the strongest regional clusters are forming, and the challenges that remain before Texas reaches its full potential.

 

The Big Picture: A connected but diverse landscape

Texas isn’t one single life sciences market – it’s a network of fast-growing hubs, each with distinct strengths. That diversity is one of its most significant advantages.

 

North Texas (Dallas–Fort Worth)

The Dallas-Fort Worth metroplex – home to roughly seven to ten million people – is one of the state’s most active regions, anchored by UT Southwestern, a world-class research institution known for its medical breakthroughs. DFW secured $1.6 billion in life sciences VC funding from 2018 to 2022, positioning it as a rapidly ascending hub.

 

Facilities like Pegasus Park in Dallas are helping to accelerate that growth. Pegasus Park, which was recently selected as the physical base for the federal ARPA-H “Customer Experience Hub,” represents a major federal vote of confidence. As Sarah Ramsay, Head of Global Quality Compliance & Improvement at Santen, notes, Pegasus Park reflects “the kind of long-term investment that’s positioning North Texas as a serious life sciences hub.”

 

Craig Gallivan, National VP of Sales & Marketing (North America) at Compumedics, describes North Texas as part of a “triangle” alongside Houston and Austin–San Antonio; large, distinct markets that function more like “separate ecosystems than a single state.” That regional independence, he adds, “is both a challenge and a strength.”

 

Houston

Houston is already a global medical powerhouse. The Texas Medical Center (TMC) alone employs around 200,000 people, making it the largest medical complex in the world and a national leader in Life Sciences Manufacturing. Add in Baylor College of Medicine, Rice University, UT MD Anderson, and a dense network of accelerators and labs, and you have a city with enormous research and clinical depth.

 

Christy Franco, Senior Director of Commercial Operations at VGXI, describes Houston’s life sciences scene as “resilient and growing,” with momentum building after Eli Lilly’s recent manufacturing investment north of the city. Houston continues to dominate life sciences funding in the state, maintaining geographic leadership across all funding categories in Q1 2025.

 

Affordability also plays a key role. Ron Gonzales, former Vice President Americas at Genetic Signatures, says that “affordable housing and no state income tax make Texas far more attractive than places like California,” where high taxes and costs have “pushed both talent and companies east.” That financial and political climate has helped Houston become one of the country’s most investable biotech locations.

 

Chris Coker, CEO of Velvet Therapeutics, emphasises another key advantage: Houston’s ecosystem fosters workforce stability and resilience. In established biotech hubs on the coasts, intense competition can result in high employee turnover.  Employees in Houston tend to stay committed even during challenging periods. This loyalty mitigates the risks associated with early-stage biotech ventures and fosters the growth of sustainable, long-term companies.

Austin–San Antonio Corridor

The Austin–San Antonio region has carved out its own identity as the state’s tech–medtech intersection. Austin, often referred to as “Silicon Hills,” is a magnet for entrepreneurs and engineers, while San Antonio adds strength in clinical research and medical education.

 

Gallivan notes that this corridor is “where tech culture meets medtech,” blending Texas’s engineering talent with growing medical expertise. The Education & Health Services sector remains fast-growing in the Austin metro area, becoming a key hub for digital health, diagnostics, and medical device innovation.

What’s driving Texas’s Life Sciences boom

The state’s rise in biotech and life sciences is powered by three core engines: talent, capital, and infrastructure.

 

A growing talent pipeline

Texas has no shortage of scientific and technical talent. It has more top-tier research universities than any other state and consistently ranks high for life sciences doctorates awarded. Key institutions include UT Austin, UT Southwestern, Rice University, Baylor College of Medicine, and UTHealth Houston.

 

Ramsay notes that university recognition in life sciences is “improving year-on-year,” and that Texas is now retaining more high-caliber researchers who previously left for coastal hubs.

Megan Livingston, a Texas native and consultant for early-stage biotech companies, agrees that Houston, in particular, is very appealing for PhDs and postdocs, due to its abundance of available high-caliber programs and low cost of living. Though long-term stability, she says, will depend on the presence of more established anchor companies to employ recent graduates.

 

Coker adds that Houston’s relative stability is a unique advantage: while it may take more effort to attract capital and recruit talent, employees in the city are less likely to leave during setbacks, providing biotech companies with a committed and resilient workforce for long-term projects.

 

Investment and funding are catching up

Historically, Texas investors focused on oil, gas, and real estate. That’s changing fast as biotech success stories attract more attention and capital.

 

Early-stage biotech companies have traditionally struggled to attract local funding, as family offices and angel investors often focus on investments in oil, gas, real estate, and livestock. However, as more Texas startups demonstrate success, these investors are beginning to recognise biotech’s potential, opening new opportunities for early-stage capital.

 

The state saw a record $1.285 billion in private capital raised in Q1 2025, concentrated in later-stage deals, signaling the ecosystem’s maturation.

 

 

Public investment remains a key driver. The Cancer Prevention and Research Institute of Texas (CPRIT) has poured more than $6 billion into cancer research and commercialisation, bridging the gap between academia and industry. Texans also approved the creation of the Dementia Prevention Research Institute of Texas (DPRIT) in the November 4th election with $3 billion in funding towards research fighting neurodegenerative disorders. Ramsay adds that while private funding remains tight, “confidence in the regional ecosystem is strong and expected to strengthen as conditions stabilise.”

 

Infrastructure that enables innovation

New life sciences parks, labs, and incubators are giving start-ups and early-stage firms the resources they need to grow locally. Notable examples include Helix Park in Houston (a $1.1 billion, 37-acre research campus), TMCx and TMC Innovation Labs in Houston, and Pegasus Park in Dallas, all designed to foster collaboration and innovation without requiring companies to relocate.

 

The Challenges: Growing pains of a young ecosystem

Despite the momentum, Texas’s life sciences community is still maturing. Gallivan notes that the state “lacks the national research prestige” of East and West Coast institutions, which have built decades-long reputations around specialised research and fellowships. For example, established hubs like California still lead the nation in NIH funding awards.

 

Compared to Boston, San Diego, or the Bay Area, Texas also has relatively few large biotech employers, making it harder for professionals to build long-term careers locally. Gonzales adds that while Texas is “pro-business and highly competitive,” the main challenge is overcoming the inertia of large, established companies reluctant to relocate.

 

At the same time, Houston’s ecosystem offers a counterbalance: while it may lack the East Coast’s agglomeration economies, it gains stability, loyalty, and persistence in its workforce—qualities that are crucial for building sustainable biotech companies.

 

The Opportunities: Why Texas has an edge

Texas’s strengths lie in its cost advantages, scale, and culture. The absence of state income tax, lower operational costs, and affordable real estate allow companies to reinvest more into R&D, manufacturing, and growth.

 

As Gonzales puts it, “Texas is very pro-business, and that attitude is exactly what’s driving the state’s rise.” The state’s low tax burden (a 0% personal income tax rate) remains a compelling factor for both employees and corporate entities.

 

Coker of Velvet Therapeutics also highlights a cultural edge: “Houston’s workforce is stable and resilient,” helping companies retain expertise in a field that demands long-term commitment.

Combined with supportive infrastructure and a growing investor base, this resilience gives Texas a unique advantage for nurturing durable, long-term biotech ventures.

 

Looking ahead: Texas on the global stage

Texas is no longer just a promising market; it’s an emerging national leader. Strong research institutions, competitive costs, expanding infrastructure, and pro-growth policies make it one of the most attractive places in the country for biotech investment.

 

Yes, there’s still work to do, with more anchor companies, more local capital, and more intercity collaboration needed. But these are growing pains, not roadblocks. The foundations are solid and the momentum is real.

 

As Christy Franco says, “There’s a lot of growth and development, especially for talent and early-stage companies. Texas is building critical mass that attracts more firms and funding.”

 

Whether you’re an investor, researcher, or founder, now’s the time to get involved. Connect with regional innovation hubs and see how your organisation can play a role in shaping the state’s biotech future.

 

Thanks again for your time in contributing to this article and for the interesting and enjoyable chats: Sarah Ramsay, Christy Franco, Ron Gonzales, Chris Coker, Craig Gallivan, and Megan Livingston.